Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2/PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-01

Study Completion Date

2023-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It is a placebo-controlled randomized trial to evaluate the efficacy and safety of GNR-038 in comparison with Berinert® in patients with hereditary angioedema

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced Angioedema

NCT01843530

Acute ACE-induced Angioedema

COMPLETED PHASE3

A Study of Navenibart in Participants With Hereditary Angioedema

NCT06842823

Hereditary Angioedema (HAE)

RECRUITING PHASE3

Angioedema Biomarker Research Study

NCT06210698

Angioedema Angioedemas, Hereditary Urticaria +5 more

NOT_YET_RECRUITING

A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants

NCT02093923

Hereditary Angioedema (HAE)

COMPLETED PHASE1

A Study to Evaluate the Irritation Potential of ATx201 in Healthy Volunteers

NCT03301870

Irritation Potential of Topic Agent

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hereditary angioedema is a rare, potentially life-threatening genetically determined disease associated with a deficiency or impairment of the functional activity of the C1-esterase inhibitor (C1-inhibitor). The main clinical manifestation of hereditary angioedema is recurrent subcutaneous or submucosal swelling of various localization. Most often, the development of the disease is based on a mutation in the SERPING1 gene. The prevalence of the disease in the world ranges from 1:10 000 to 1:150 000. GNR-038 is a recombinant C1 inhibitor (rhC1INH), which is a complete structural and functional analog of the plasma C1 inhibitor. Phase I study results showed convincing safety and tolerability evidence of GNR-038.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hereditary Angioedema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Two-stage study. In the first stage - 4 groups are presented. At the second stage - 2 study groups 200 HAE attacks to be randomized in 50 patients

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

At the first stage - the study will be blinded, at the second stage - open-label

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study stage 1: GNR-038, 50 МЕ/ kg

Recombinant C1 esterase inhibitor

Group Type EXPERIMENTAL

GNR-038, 50 МЕ/ kg

Intervention Type DRUG

A single intravenous infusion of GNR-038, 50 МЕ/ kg less than 5 hours after the onset of edema.

Study stage 1: GNR-038, 100 МЕ/ kg

Recombinant C1 esterase inhibitor

Group Type EXPERIMENTAL

GNR-038, 100 МЕ/ kg

Intervention Type DRUG

A single intravenous infusion of GNR-038, 100 МЕ/ kg less than 5 hours after the onset of edema.

Study stage 1: Berinert®, 20 МЕ/ kg

Human C1 esterase inhibitor

Group Type EXPERIMENTAL

Berinert®, 20 МЕ/ kg

Intervention Type DRUG

A single intravenous infusion of Berinert®, 20 МЕ/ kg less than 5 hours after the onset of edema.

Study stage 1: Placebo

Placebo

Group Type EXPERIMENTAL

Placebo

Intervention Type DRUG

A single intravenous infusion of Placebo less than 5 hours after the onset of edema.

Study stage 2: GNR-038 in selected dose

Recombinant C1 esterase inhibitor

Group Type EXPERIMENTAL

GNR-038. The dose will be selected according to results of stage 1 clinical trial.

Intervention Type DRUG

A single intravenous infusion of GNR-038 less than 5 hours after the onset of edema.

Study stage 2: Berinert®, 20 МЕ/ kg

Human C1 esterase inhibitor

Group Type EXPERIMENTAL

Berinert®, 20 МЕ/ kg

Intervention Type DRUG

A single intravenous infusion of Berinert®, 20 МЕ/ kg less than 5 hours after the onset of edema.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GNR-038, 50 МЕ/ kg

A single intravenous infusion of GNR-038, 50 МЕ/ kg less than 5 hours after the onset of edema.

Intervention Type DRUG

GNR-038, 100 МЕ/ kg

A single intravenous infusion of GNR-038, 100 МЕ/ kg less than 5 hours after the onset of edema.

Intervention Type DRUG

Berinert®, 20 МЕ/ kg

A single intravenous infusion of Berinert®, 20 МЕ/ kg less than 5 hours after the onset of edema.

Intervention Type DRUG

Placebo

A single intravenous infusion of Placebo less than 5 hours after the onset of edema.

Intervention Type DRUG

GNR-038. The dose will be selected according to results of stage 1 clinical trial.

A single intravenous infusion of GNR-038 less than 5 hours after the onset of edema.

Intervention Type DRUG

Berinert®, 20 МЕ/ kg

A single intravenous infusion of Berinert®, 20 МЕ/ kg less than 5 hours after the onset of edema.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Recombinant C1 esterase inhibitor, 50 МЕ/ kg Recombinant C1 esterase inhibitor, 100 МЕ/ kg Human C1 esterase inhibitor Recombinant C1 esterase inhibitor. Human C1 esterase inhibitor

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Men and women 18 years and older at the time of signing the Informed Consent Form.
2. Availability of written informed consent signed by the patient prior to the start of any procedures related to the study.
3. Confirmed diagnosis of HAE:

* C4 level \<50% of the lower limit of the range of normal laboratory values and one of the points below:
* the C1INH level \<50% of the lower limit of the range of normal laboratory values, OR
* the level of C1INH within normal values, while the level of functional activity of C1INH is below 50% of the lower limit of the range of normal values.
4. Localization of the edema in the abdominal cavity, in the face area (lips, eyelids, subcutaneous tissue), limbs, trunk or in the area of the external genitals in the anamnesis.
5. ≥4 HAE attacks requiring treatment or causing significant functional impairment for 2 consecutive months in the 3-month period prior to Screening, properly documented in the medical records.
6. Patient's consent to adhere to reliable methods of contraception.

Exclusion Criteria

1. Deviation of the C1q level below the normal limit.
2. B-cell lymphoproliferative diseases in the anamnesis or at the time of inclusion in clinical trial.
3. The presence of anti-C1INH autoantibodies.
4. Allergic reactions to the components of C1INH drugs or other blood components.
5. Glomerular filtration rate ≤59 ml/min/1.73 m2, calculated by the formula CKD-EPI Creatinine Equation (2009) (see Appendix).
6. The concentration of peripheral blood leukocytes \>20\*109/L.
7. Drug addiction, solvent abuse, alcoholism in the anamnesis or at the time of inclusion.
8. Participation in clinical trials of C1-esterase inhibitor drugs, blood transfusion and its components during the last 90 days prior to screening.
9. Participation in clinical trials of any other investigational drugs within the last 30 (thirty) days prior to screening.
10. Positive laboratory results for HIV and hepatitis B and C.
11. Pregnancy and lactation.
12. Diseases and conditions associated with thrombosis (myocardial infarction, transient ischemic attacks, deep and superficial vein thrombosis, and pulmonary embolism) less than 6 months before the start of the screening period, as well as an increased risk of arterial or venous thrombosis according to the study doctor's opinion.
13. Concomitant diseases and conditions that according to the study doctor's opinion put the patient's safety at risk when participating in the study, or that will affect the analysis of safety data if this disease/condition worsens during the study, including:

* Mental illness;
* Diseases of the immune and endocrine system that are not controlled by drug therapy (including decompensated diabetes mellitus and thyroid diseases);
* Hematological diseases requiring chemotherapy;
* Cancer or cancer in the past medical history, with the exception of cured basal cell carcinoma;
* Decompensated liver diseases.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No